Company: LGNZZ
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0000886163-25-000025
Chunk: 67

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 67
---
520,339 |     |                                                    | 6,211,312 |

(3) Amounts represent compensation actually paid to our PEO and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:

| Year |     | PEO                           |     | Non-PEO NEOs                                                                               |
| 2024 |     | Todd C. Davis                 |     | Matthew Korenberg, Tavo Espinoza, and Andrew Reardon                                       |
| 2023 |     | Todd C. Davis                 |     | Matthew Korenberg, Tavo Espinoza, and Andrew Reardon                                       |
| 2022 |     | Todd C. Davis,John L. Higgins |     | Matthew Korenberg, Tavo Espinoza, Andrew Reardon, Matthew W. Foehr, and Charles S. Berkman |
| 2021 |     | John L. Higgins               |     | Matthew Korenberg, Matthew W. Foehr, and Charles S. Berkman                                |
| 2020 |     | John L. Higgins               |     | Matthew Korenberg, Matthew W. Foehr, and Charles S. Berkman                                |

(4) The Peer Group TSR set forth in this table utilizes the Nasdaq Biotechnology Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2024. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Nasdaq Biotechnology Index, respectively, assuming all dividends are reinvested. Historical stock performance is not necessarily indicative of future stock performance.

The amounts reported in the “Compensation Actually Paid to PEO” and “Average Compensation Actually Paid to Non-PEO NEOs” columns do not reflect the actual compensation paid to or realized by the individuals serving as our Chief Executive Officer or our non-PEO NEOs during each applicable year. The calculation of compensation actually paid for purposes of this table includes point-in-time fair values of stock awards and these values will fluctuate based on our stock price, various accounting valuation assumptions and projected performance related to our performance awards. See the Summary Compensation Table for certain other compensation paid to the individuals serving as our Chief Executive Officer and our non